Skolnick et al. TIBTECH, Jan. 2000. vol. 18, pp. 34-39, 2000.* |
Ngo. et al. The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 433, 492 & 495, 1994.* |
Mery et al. Birkhauser, Boston, MA.* |
Huang et al. Pharmacology and Therapeutics vol. 86 pp. 201-215, 2000.* |
Takahashi et al., J. Invest. Derm., vol. 101:431, 1993, Sep. 1993.* |
Tewari et al., J. Bio. Chem., vol. 270:3255-3260, 1995, Feb. 1995.* |
Bianchi et al., J. Invest. Derm., vol. 103:829-833, 1994, Dec. 1994.* |
Lerner, Nature, vol. 299: 592-596, 1982, Oct. 1982.* |
Hibino, “Cloning of Psoriastatin, A Cathespin L-Specific Inhibitor, from Psoriatic Epidermis”, Mol. Biology of the Cell 6:345a (1995) Abstract 2007. |
Takahashi, “Structure and Inhibitory Effect of Psoriatic Tissue-Derived Cathespin L-Specific Inhibitor (Psoriastatin)” Mol. Biology of the Cell 5:367a (1994) Abs. 2132. |
Hibino, “Cloning of Two Distinct Types of Psoriastatin cDNAs From Psoriatic Epidermis” J. of Invest. Dermatology 106(4):874 (1996) Abstract 414. |
Takahashi, “Cathespin L-Specific High Molecular Weight Cystein Proteinase Inibitor (Psoriastatin) from Psoriatic Scales” J. Invest. Dermatology 101(3):431 Abs. 261. |
Schneider, S.S. et al., A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc. Natl. Acad. Sci. USA 92:3147-3151 (1995). |